MediBeacon
MediBeacon is a medical technology company specializing in fluorescent tracer agents and transdermal measurement technology to improve patient care. Their focus is on developing solutions for organ function assessment, including kidney, eye, and other vital organ systems, through innovative optical diagnostic platforms. They aim to provide practical, cost-effective healthcare solutions and are involved in clinical and preclinical research to advance fluorescence-based disease monitoring. The company is committed to global health impact through technology development and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
MediBeacon
425 N. New Ballas Road, Suite 100, St. Louis, MO 63141
Patents
Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflecting medium with time-varying optical properties
US-12257048-B2
View DetailsUses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy
US-12102432-B2
View Details
Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflecting medium with time-varying optical properties
US-12257048-B2
View DetailsUses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy
US-12102432-B2
View DetailsProducts
Regulatory‑approved transdermal kidney function measurement system
A non‑invasive clinical system that detects clearance kinetics of an injected fluorescent GFR tracer at the skin surface and reports a transdermal GFR metric for clinical renal assessment; the system has obtained device approvals in multiple jurisdictions.
Preclinical transdermal monitoring system (monitor kit)
A preclinical monitor kit for measuring tracer kinetics transdermally in rodents, combined with desktop analysis software and validated small‑animal protocols to enable non‑terminal, repeated clearance measurements.
Analysis software for fluorescence kinetic data
Desktop analysis software suite (basic and advanced tiers) providing acquisition, advanced evaluation algorithms, experiment/database management and raw data export for research and clinical workflows.
Regulatory‑approved transdermal kidney function measurement system
A non‑invasive clinical system that detects clearance kinetics of an injected fluorescent GFR tracer at the skin surface and reports a transdermal GFR metric for clinical renal assessment; the system has obtained device approvals in multiple jurisdictions.
Preclinical transdermal monitoring system (monitor kit)
A preclinical monitor kit for measuring tracer kinetics transdermally in rodents, combined with desktop analysis software and validated small‑animal protocols to enable non‑terminal, repeated clearance measurements.
Analysis software for fluorescence kinetic data
Desktop analysis software suite (basic and advanced tiers) providing acquisition, advanced evaluation algorithms, experiment/database management and raw data export for research and clinical workflows.
Services
Sale and technical support of preclinical transdermal monitoring systems and associated tracer reagents for laboratory research.
Collaborative partnerships to advance tracer‑based transdermal technologies through feasibility studies and clinical trials to establish clinical utility.
Collaborative R&D programs to explore new clinical uses of fluorescent tracer agents and transdermal detection (for example, ocular angiography, gut permeability, intraoperative visualization).
Establishing regional commercialization agreements and investor relations to facilitate market access and distribution.
Licensing and support services for desktop analysis software offering raw data export, advanced evaluation algorithms and database experiment management for research and clinical workflows.
Sale and technical support of preclinical transdermal monitoring systems and associated tracer reagents for laboratory research.
Collaborative partnerships to advance tracer‑based transdermal technologies through feasibility studies and clinical trials to establish clinical utility.
Collaborative R&D programs to explore new clinical uses of fluorescent tracer agents and transdermal detection (for example, ocular angiography, gut permeability, intraoperative visualization).
Establishing regional commercialization agreements and investor relations to facilitate market access and distribution.
Licensing and support services for desktop analysis software offering raw data export, advanced evaluation algorithms and database experiment management for research and clinical workflows.
Expertise Areas
- Transdermal organ function assessment
- Fluorescent tracer agent development and formulation
- Preclinical transdermal monitoring and small‑animal protocols
- Point‑of‑care renal function measurement using transdermal clearance
Key Technologies
- Fluorescent tracer agents
- Transdermal optical fluorescence detection
- Wearable optical skin sensors
- Portable small‑animal fluorescence monitors
News & Updates
MediBeacon, a St. Louis-based optical diagnostic company, won the 2012 St. Louis Regional Business Plan Competition, receiving a $50,000 grant and professional services to develop their platform for real-time kidney monitoring using fluorescent tracer agents.
MediBeacon's Transdermal GFR System has received FDA approval for assessing kidney function, representing a significant advancement in non-invasive renal monitoring.
MediBeacon's Transdermal GFR System has received FDA approval for assessing kidney function, representing a significant advancement in non-invasive renal monitoring.
MediBeacon was recognized for its innovative platform for monitoring kidney function using fluorescent tracers.
MediBeacon, a St. Louis-based optical diagnostic company, won the 2012 St. Louis Regional Business Plan Competition, receiving a $50,000 grant and professional services to develop their platform for real-time kidney monitoring using fluorescent tracer agents.
MediBeacon's Transdermal GFR System has received FDA approval for assessing kidney function, representing a significant advancement in non-invasive renal monitoring.
MediBeacon's Transdermal GFR System has received FDA approval for assessing kidney function, representing a significant advancement in non-invasive renal monitoring.
MediBeacon was recognized for its innovative platform for monitoring kidney function using fluorescent tracers.